Cardiocenter, Department of Cardiology, 3 Medical School, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
PLoS One. 2013;8(2):e53860. doi: 10.1371/journal.pone.0053860. Epub 2013 Feb 18.
Apoptosis plays an important role in the development of heart failure. The aim of the prospectively designed study was to assess whether the concentration of apoptotic markers apoptosis-stimulating fragment (Fas, CD95/APO-1) and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) can predict prognosis in patients with acute coronary syndromes.
The concentrations of soluble Fas and TRAIL were determined in 295 patients with acute coronary syndromes. The status of all patients was evaluated at 6 months. The primary goal was a composite end-point of death and hospitalization for heart failure. The secondary end-points were re-MI, death alone and stroke alone.
During the median follow-up of 6 months, 26 patients experienced the composite end-point. Using multivariate logistic regression, the concentration of TRAIL was the strongest significant and independent predictor of composite end-point (OR 0.11 (95% CI 0.03-0.45), p = 0.002). Low concentration was associated with poor prognosis of patients. Other significant predictors of composite end-point were serum creatinine (OR 7.7 (95% CI 1.1-54.5, p = 0.041) and complete revascularization (OR 0.19 (95% CI 0.05-0.78, p = 0.02). Independent significant predictors of death in the multivariate analysis were the concentration of TRAIL (OR 0.053 (95% CI 0.004-0.744), p = 0.029), older age (OR 1.20 (95% CI 1.02-1.41, p = 0.026) and serum creatinine (OR 15.1 (95% CI 1.56-145.2), p = 0.0193). Re-MI or stroke could not be predicted by any combination of obtained parameters.
Low concentrations of soluble TRAIL represent a strong predictor of a poor prognosis in patients with acute coronary syndrome. The predictive value of TRAIL concentration is independent of age, ejection fraction, index peak troponin level, concentration of BNP or serum creatinine.
细胞凋亡在心力衰竭的发生发展中起着重要作用。本前瞻性设计研究旨在评估凋亡标志物凋亡刺激片段(Fas,CD95/APO-1)和肿瘤坏死因子相关凋亡诱导配体(TRAIL)的浓度是否可预测急性冠脉综合征患者的预后。
测定 295 例急性冠脉综合征患者可溶性 Fas 和 TRAIL 的浓度。所有患者在 6 个月时进行评估。主要终点是死亡和心力衰竭住院的复合终点。次要终点是再心肌梗死、单纯死亡和单纯卒中等。
在中位随访 6 个月期间,26 例患者出现复合终点。使用多变量逻辑回归,TRAIL 浓度是复合终点的最强显著独立预测因子(OR 0.11(95%CI 0.03-0.45),p=0.002)。低浓度与患者预后不良相关。复合终点的其他显著预测因子还包括血清肌酐(OR 7.7(95%CI 1.1-54.5,p=0.041)和完全血运重建(OR 0.19(95%CI 0.05-0.78,p=0.02)。多变量分析中死亡的独立显著预测因子是 TRAIL 浓度(OR 0.053(95%CI 0.004-0.744),p=0.029)、年龄较大(OR 1.20(95%CI 1.02-1.41,p=0.026)和血清肌酐(OR 15.1(95%CI 1.56-145.2),p=0.0193)。任何获得的参数组合都不能预测再心肌梗死或卒中。
可溶性 TRAIL 浓度低是急性冠脉综合征患者预后不良的强预测因子。TRAIL 浓度的预测价值独立于年龄、射血分数、峰值肌钙蛋白水平指数、BNP 浓度或血清肌酐。